E. Jaller

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)

R. Rosell, A. Cardona, L. Raez, 2022, Frontiers in Oncology.

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation

R. Rosell, A. Cardona, O. Arrieta, 2021, Journal of Neuro-Oncology.

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

R. Rosell, A. Cardona, O. Arrieta, 2021, Therapeutic advances in respiratory disease.

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).

Diego F. Chamorro, M. Burotto, R. Rosell, 2022, Lung cancer.

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study

R. Rosell, A. Cardona, L. Raez, 2023, Targeted Oncology.

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).

M. Burotto, R. Rosell, A. Cardona, 2022, Clinical lung cancer.

EP16.03-003 Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)

L. Raez, O. Arrieta, U. Malapelle, 2022, Journal of Thoracic Oncology.